Recombinant Human Insulin-like growth factor-binding protein 6 (IGFBP6)

1. A decrease of IGFBP6 expression can involve a decrease in the expression of N-cadherin and transcription factor Slug. PMID: 29577195
2. IGFBP-6 could inhibit invasion and migration of colorectal carcinoma cells PMID: 29439316
3. IGFBP6 might be an important regulator and prognostic factor for glioma. PMID: 27650075
4. Results suggest that insulin like growth factor binding protein 6 (IGFBP6) may be an independent prognostic biomarker for nasopharyngeal carcinoma (NPC). PMID: 27623076
5. We identified a novel SNP variant, Chr12:g.53494591T>C. c.T430C (p.S144P) in the insulin-like growth factor binding protein-6 (IGFBP6) gene. This variant was shared by all affected family members, but not by unaffected members. The c.T430C (p.S144P) variant of IGFBP6 was identified as the likely causal variant associated with increased risk of familial disc degeneration in the studied pedigree. PMID: 28829625
6. We found that IGFBP6 and SATB2 were significantly down-regulated in HIV-infected CEM*174 cells and 3 different cohorts of HIV/AIDS patients while their promoters were predominantly hyper-methylated compared with normal controls. PMID: 26039376
7. IGFBP6 attenuation in ACTH-secreting pituitary adenomas is associated with tumor growth, through activation of PI3K-AKT-mTOR pathway PMID: 24379119
8. CCL-18 and IGFBP-6 were identified as new potential serum biomarkers for prostate cancer. PMID: 24747338
9. When the concentrations of IGFBP-6 or KNG1 were greater than 98.5 pg/ml or 88.5 ng/ml, respectively, they predicted the proliferative vitreoretinopathy prognosis. PMID: 23808406
10. Data indicate that IGFBP-6 binds to prohibitin-2 on the cell membrane, and knockdown of the latter abrogates IGFBP-6-induced migration. PMID: 24003225
11. Review of the IGF system in physiology and disease with a focus on the regulation and actions of IGFBP-6, and its potential roles in cancer cells. PMID: 23126425
12. These results suggest that the expression of IGFBP-6 in vascular endothelial cells is up-regulated by hypoxia and IGFBP-6 inhibits angiogenesis in vitro and in vivo PMID: 21618524
13. IGFBP-6 acts as a inhibitory mediator of thyroid hormone effects in osteoblast differentiation PMID: 21997736
14. TCDD at low concentrations may have a negative effect on cell apoptosis and down-regulate gene expression of IGFBP-6 in SaOS-2 cells. PMID: 18724896
15. Hh pathway is aberrant activation in colorectal carcinoma cell line. Its inhibitor may be effectual agent for colorectal cancer chemoprevention. Gli1 maintained cell survival by binding promoter regions and facilitating transcription of IGFBP6 and Bcl-2. PMID: 21940310
16. When IGFBP-6 gene expression was downregulated, cell proliferation was inhibited and apoptotic cell death was increased. PMID: 21820463
17. Kininogen-1 and IGFBP-6 are expressed in serum and vitreous humor in proliferative vitreoretinopathy patients. PMID: 21054968
18. IGFBP-6 inhibits osteoblastic differentiation mediated by vitamin d3 by directly binding the vitamin d receptor and inhibiting its function PMID: 21458526
19. These results indicate that IGFBP-6 promotes Rh30 rhabdomyosarcoma chemotaxis in an IGF-independent manner, and that MAPK signaling pathways and their cross-talk play an important role in this process. PMID: 20432455
20. Inhibition of human osteoblast marker gene expression by retinoids is mediated in part by insulin-like growth factor binding protein-6. PMID: 11914024
21. may function as an antiproliferative molecule suppressing mitogenic effects of insulin-like growth factors on Malassez cells PMID: 12558805
22. CCI-779 acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo. PMID: 14710364
23. C-domain of IGFBP-6 consists of a thyroglobulin type 1 fold comprising an alpha-helix followed by a loop, a three-stranded antiparallel beta-sheet incorporating a second loop, and a disulfide-bonded flexible third loop. PMID: 15308688
24. A close correlation exists between residues of the carboxyl-terminal domain of IGFBP6 undergoing conformational change in 15N NMR spectroscopy studies with those that disappeared or broadened upon insulin-like growth factor (IGF-II) binding. PMID: 15366928
25. The IGFBP-6 protein is synthesized as propeptides with a hydrophobic leader sequence, removal of which yields a mature protein composed of 3 recognizable domains of similar size. PMID: 15797461
26. transgenic human IGFBP-6 mice may be considered a new tool for studies of the involvement of the brain IGF system in metabolism control and obesity. PMID: 15889232
27. p38 MAPK is involved in IGFBP-6-induced IGF-independent rhabdomyosarcoma cell migration PMID: 17519236
28. Toxic effect of TCDD on osteogenesis through altering IGFBP6 gene expression in osteoblasts is reported. PMID: 17978469
29. IGFBP-6 is translocated to the nucleus with functional consequences, and different members of the IGFBP family have specific nuclear import mechanisms. PMID: 18039785
30. These studies provide evidence that overexpression of IGFBP-6 suppresses human and murine osteoblast differentiation, that IGFBP-6 and LMP-1 physically interact, and supports the conclusion that this interaction may be functionally relevant. PMID: 18395833
31. bexarotene increased the occupancy of the identified enhancer element in IGFBP-6 gene by RXRalpha, RARbeta, cJun, cFos, and p300 PMID: 18957410
32. Data show that an increase in JNK activation in the presence of NFkappaB inhibition significantly increased the expression of IGFBP6. PMID: 18982452
33. IGFBP-6 is the effector of tumor suppressor activity of SEMA3B. PMID: 18985860

Show More

Hide All

HGNC: 5475

OMIM: 146735

KEGG: hsa:3489

STRING: 9606.ENSP00000301464

UniGene: Hs.274313